NCT02532374View on ClinicalTrials.gov

Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

February 29, 2016

Conditions
Smoking
Interventions
OTHER

Nicorette® inhalator

Subjects will inhale the Nicorette® inhalator (15 mg) at the rate of one deep inhalation every 15 seconds on average, over approximately 20 minutes (80 inhalations in total).

OTHER

P3L

Subjects will inhale P3L (50 µg/puff, 80 µg/puff and 150 µg/puff) at the rate of one inhalation every 30 seconds on average, over approximately 6 minutes (i.e., 12 inhalations in total).

Trial Locations (1)

8011

Christchurch Clinical Studies Trust Ltd (CCST), Christchurch

All Listed Sponsors
lead

Philip Morris Products S.A.

INDUSTRY

NCT02532374 - Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L | Biotech Hunter | Biotech Hunter